View Older Stories View More Recent Stories
-
Ultragenyx Pharma (RARE) PT Lowered to $60 at H.C. Wainwright
-
Ultragenyx Pharma (RARE) PT Lowered to $52 at Guggenheim
-
Ultragenyx Pharma (RARE) PT Lowered to $58 at BofA Securities
-
Leerink on Ultragenyx Pharma (RARE): 'DTX401 Rolling BLA Submitted, Setting Up Launch for Underappreciated Program'
-
Ultragenyx completes gene therapy application for rare metabolic disease
-
Ultragenyx Pharma (RARE) PT Lowered to $45 at Wells Fargo
-
Ultragenyx Pharma (RARE) PT Lowered to $63 at Jefferies
-
Jefferies Downgrades Mereo BipPharma Group (MREO) to Hold
-
Ultragenyx Pharma (RARE) PT Lowered to $71 at Goldman Sachs
-
Ultragenyx Pharma (RARE) PT Lowered to $70 at Leerink Partners
-
Mereo BipPharma Group (MREO) PT Lowered to $2 at Leerink Partners
-
TD Cowen Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
LifeSci Capital Downgrades Mereo BipPharma Group (MREO) to Market Perform
-
Ultragenyx Pharma (RARE) PT Lowered to $47 at Baird
-
Ultragenyx Pharma (RARE) PT Lowered to $50 (from $103) at Citi
-
William Blair Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
-
Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
-
Morgan Stanley Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
-
Truist Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
Ultragenyx Pharma (RARE) halted, news pending
-
Cantor Fitzgerald Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
-
Citi Opens 90-Day Upside Catalyst Watch on Ultragenyx Pharma (RARE)
-
Ultragenyx Pharma (RARE) PT Lowered to $72 at RBC Capital
-
Ultragenyx Pharma (RARE) Misses Q3 EPS by 58c, provides guidance
-
Ultragenyx Pharma (RARE) January 50 calls active
-
Cantor Fitzgerald Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
-
H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
Ultragenyx begins rolling FDA submission for GSDIa gene therapy
-
H.C. Wainwright Assumes Ultragenyx Pharma (RARE) at Buy
-
Health Canada approves Evkeeza for infants as young as 6 months with HoFH
-
Ultragenyx Pharma (RARE) December options active
-
Ultragenyx stock falls after FDA issues complete response letter for gene therapy
-
Ultragenyx receives FDA rejection for gene therapy to treat rare disease
-
TD Cowen: 'Ultragenyx Pharma (RARE) a Buying Oppy Ahead Of Dec '25 Readout'
-
BTIG Reiterates Buy Rating on Mereo BipPharma Group (MREO)
-
Morgan Stanley Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
-
Canaccord Genuity Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
Ultragenyx Pharma (RARE) PT Lowered to $65 at Wells Fargo
-
BofA Securities on Ultragenyx Pharma (RARE): 'top 2025 pick'
-
Goldman Sachs Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
Citi Opens 90d Upside Cat Call on Ultragenyx Pharma (RARE)
-
After-hours movers: WK Kellogg, Costco, Ultragenyx Pharma
-
Ultragenyx and Mereo advance UX143 osteogenesis imperfecta study to final analysis
-
Ultragenyx Pharma (RARE) Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
-
TD Cowen's Best Smidcap Ideas 2025
-
William Blair Starts Ultragenyx Pharma (RARE) at Outperform
-
Ultragenyx Pharma (RARE) Misses Q1 EPS by 1c, provides guidance
-
Ultragenyx Pharma (RARE) spreader of 1K contracts of July 30 puts, July 40 calls and July 50 calls
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
Mereo and Ultragenyx remain top picks at Cantor Fitzgerald

